Imaging Endpoints congratulates Anthony G. Letai, MD, PhD, on his well-deserved appointment as the 18th Director of the National Cancer Institute (NCI). Dr. Letai was sworn in on September 29, 2025, by Health and Human Services Secretary Robert F. Kennedy,… Read More
While the Response Assessment in Neuro-Oncology (RANO) Working Group criteria have been pivotal in assessing adult high-grade gliomas, the more recently established Response Assessment in Pediatric Neuro-Oncology (RAPNO) criteria address the unique challenges of evaluating pediatric gliomas, emphasizing the need… Read More
In clinical trials evaluating new therapies for lymphoma, the disease assessments are primarily driven by the Lugano Classification 2014 and rely heavily on PET avidity and changes in measurable disease. These objective measures are critical for standardizing evaluations and ensuring… Read More
Immunotherapy has transformed cancer treatment by harnessing the body’s natural defenses to target and destroy cancer cells. However, evaluating its effectiveness presents unique challenges. Imaging is crucial—not only for monitoring tumor response and detecting distinctive patterns like pseudoprogression, but also… Read More
Radiopharmaceutical therapies (RPTs) are transforming cancer treatment by combining radiation with targeted drug delivery. These therapies require a delicate balance between effectiveness and safety, especially considering the unique long-term risks of radiation exposure. The FDA recently released a draft guidance… Read More
Featured Webinar:
Radiologic Analysis of COVID-19 Infection
June 23, 2020
